Santarus Inc. and Pharming Group Announce New Data From Open-Label Repeat Treatment Study With RUCONEST (Recombinant Human C1 Esterase Inhibitor)

SAN DIEGO & LEIDEN, Netherlands--(BUSINESS WIRE)--Santarus, Inc. (NASDAQ:SNTS) and Pharming Group NV (NYSE Euronext: PHARM) announced that new data from an open-label extension of the pivotal Phase III clinical study with RUCONEST® (recombinant human C1 esterase inhibitor, or rhC1INH) will be featured in a poster presentation on November 9 & 10, 2013 at the 2013 American College of Allergy, Asthma & Immunology Annual Scientific Meeting at the Convention Center in Baltimore, Maryland. The poster is titled, Efficacy and Safety of Recombinant Human C1 Esterase Inhibitor for Acute Attacks of Hereditary Angioedema: An Open-Label Study.

Help employers find you! Check out all the jobs and post your resume.